1. Home
  2. GOVX vs CHGA Comparison

GOVX vs CHGA Comparison

Compare GOVX & CHGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

N/A

Current Price

$0.17

Market Cap

3.0M

Sector

Health Care

ML Signal

N/A

Logo Change Agents Corporation Common Stock

CHGA

Change Agents Corporation Common Stock

N/A

Current Price

$1.01

Market Cap

3.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GOVX
CHGA
Founded
2001
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0M
3.0M
IPO Year
1996
2015

Fundamental Metrics

Financial Performance
Metric
GOVX
CHGA
Price
$0.17
$1.01
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $10.00
N/A
AVG Volume (30 Days)
★ 111.0K
49.8K
Earning Date
11-12-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 33.18
EPS
N/A
★ N/A
Revenue
★ $2,489,145.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.17
$0.25
52 Week High
$1,425.00
$3.02

Technical Indicators

Market Signals
Indicator
GOVX
CHGA
Relative Strength Index (RSI) 8.96 30.64
Support Level N/A $0.25
Resistance Level $8.64 $2.54
Average True Range (ATR) 0.16 0.20
MACD -0.15 -0.07
Stochastic Oscillator 0.00 7.39

Price Performance

Historical Comparison
GOVX
CHGA

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

About CHGA Change Agents Corporation Common Stock

Change Agents Corp is an artificial intelligence software company focused on developing agentic AI applications designed to help small businesses, brands, and content creators increase revenue, improve digital discoverability, and automate content creation. The company's current portfolio includes Beacon, an AI Search Optimization platform, and Catch-Up, an autonomous AI-powered content creation platform. Through its scalable Software-as-a-Service (SaaS) business model, it is focused on delivering AI solutions that create measurable customer value while generating recurring subscription revenue and long-term shareholder returns.

Share on Social Networks: